AKT1 and ovarian carcinoma: The combination of niraparib and a mouse PD-1 blocking antibody was next evaluated in a BRCA1-deficient ovarian carcinoma syngeneic model (BRKras) previously established to resemble features of human metastatic serous ovarian cancer38,39, which also harbors the KrasG12D mutation, expresses c-Myc and Akt and is TP53-null.